- Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC.
- Clarke NW, Lovely B.
- OncLive. 2023 Feb 16.
- Conference report
- Free Full Text
•• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2023 Feb 16.)